Research demonstrates that sublingual semaglutide achieves therapeutic concentrations comparable to injectable formulations when administered with correct technique
FDA also emphasized that it intends to take enforcement actions against misleading direct-to-consumer advertising and marketing, referring back to the warning letters FDA issued in fall 2025
In 2021, the FDA approved the semaglutide formulation Wegovy for weight loss, based largely on the STEP trial that demonstrated a 12.4% average loss in body weight over the course of a year [8-9]
A licensed healthcare provider must determine whether Sermorelin therapy is clinically appropriate
The peptide carries a fatty-acid chain that binds albumin and extends its half-life, which supports once-weekly subcutaneous administration in clinical trials
Yes, when prescribed and monitored by a qualified provider, peptides are generally safe and well-tolerated